By Meredith Wadman

Although the final fate of the blockbuster diabetes drug Avandia (rosiglitazone) remains to be determined later this year by the US Food and Drug Administration, the damage to the family of ‘PPAR-gamma ligand’ drugs to which it belongs has already largely been done.

(Click here to continue reading)

Image by rselph via Flickr Creative Commons